TNF-Blockers: Infection and Cancer Risks

Explore safety/mechanism links for TNF-blocker associated infections and malignancies

Abstract

TNF-blockers demonstrate mechanistically coherent infection risks linked to TNF’s essential role in immune surveillance and host defense. While overall infection risk shows only modest increases (OR 1.18-1.20) that become non-significant when adjusted for exposure time (IRR 1.01), opportunistic infections show consistent 90% increased risk (OR 1.90) and tuberculosis risk increases 3- to 4-fold (OR 3.3-3.5). The mechanism centers on disruption of granuloma formation, explaining why tuberculosis occurs exclusively with monoclonal antibodies that completely neutralize TNF and why 72% of infliximab-associated granulomatous infections occur within 90 days, consistent with reactivation of latent infections rather than increased susceptibility to new pathogens. Agent-specific differences are substantial, with infliximab carrying 3.25-fold greater granulomatous infection risk than etanercept.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

• Records from Elicit search: n = 200
• Papers screened out: n = 190
• Papers included for extraction: n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine. The search returned 200 total results from Elicit.

Screening

• TNF-Blocker Intervention: Does this study include patients treated with TNF-blocker medications?
• Safety or Mechanistic Outcomes: Does this study report on infections and/or malignancies as outcomes OR provide mechanistic insights?
• Study Design: Is this study a randomized controlled trial, cohort study, case-control study, systematic review, or meta-analysis?
• Adult Population: Does this study include adult patients?
• Clinical Indication: Are the TNF-blockers used for treating immune-mediated inflammatory diseases?
• TNF-Specific Focus: Does this study focus on TNF-blockers specifically?
• Adequate Sample Size: If this is a case report or case series, does it include 5 or more patients?
• Original Human Clinical Data: Does this study report original human clinical data?

Infection Outcomes

• E. Dommasch et al., 2011
  • OR 1.18 (95% CI 1.05-1.33)
• S. Minozzi et al., 2016
  • OR 1.20 (95% CI 1.08-1.34)
• R. Pereira et al., 2017
  • IR 4.02/100 patient-years (95% CI 3.20-5.04) for serious infections

Malignancy Outcomes

• E. Dommasch et al., 2011
  • OR 1.48 (95% CI 0.71-3.09) for all-site malignancy
• M. Muller et al., 2020
  • 1.0% overall occurrence, no significant association in 10/11 studies.
• S. Bonovas et al., 2016
  • OR 0.90 (95% CI 0.54-1.50)

Mechanistic Insights

TNF plays a critical role in immune surveillance and host defense. For infections, TNF-α antagonists suppress pathways essential for immune defense, and granuloma formation is key for tuberculosis reactivation. For malignancies, competing mechanisms have been proposed. TNF may suppress tumor development and uncontrolled inflammation may potentiate it.

Risk Factors and Population Heterogeneity

Older age increased infection risk; concomitant immunosuppressive therapy represented an important modifier. Higher systemic inflammation levels increased lymphoma risk independently of treatment. Dose-dependent malignancy risk was observed.

Synthesis

TNF-blockers demonstrate a mechanistically coherent increased risk of opportunistic infections, particularly tuberculosis reactivation, and malignancies. For malignancies, the preponderance of evidence suggests no overall increased risk, while skin cancers may be modestly increased, particularly with combination immunosuppression.